Inhibitors of HMG-CoA Reductase: Current and Future Prospects.

Narender Singh, Joaquín Tamariz, Germán Chamorro, Jose L Medina-Franco

Journal: Mini reviews in medicinal chemistry 2010;9(11):1272-83

PMID: 19929805

Abstract

High levels of cholesterol are a primary risk factor in the development of cardiovascular diseases. In this review, we have summarized the structural, chemical and computational aspects of hypocholesterolemic drugs, both statins and non-statins, that target enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) to block cholesterol biosynthesis.

Address: Torrey Pines Institute for Molecular Studies, Port St. Lucie, Florida 34987, USA.

DOI: 10.2174/138955709789878105

Link outs

Free resources

Medical:

https://medlineplus.gov/cholesterolmedicines.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Allylbenzene Derivatives, Anisoles, Anticholesteremic Agents, Binding Sites, Cardiovascular Diseases, Cholesterol, Databases, Protein, Humans, Hydroxymethylglutaryl CoA Reductases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipoproteins, LDL, Structure-Activity Relationship